From the Journals
FDA & Government News

Obesity Medications Get New Guidance

Panel outlines pharmacotherapy roles across obesity complications and long-term weight management.

Share

  • 1

    Semaglutide and tirzepatide show significant weight loss in obese patients.

  • 2

    Semaglutide has reduced cardiovascular mortality.

  • 3

    Tirzepatide requires fewer serious adverse event reports.

  • 4

    Continued therapy for obesity drugs results in greater weight reduction.

  • 5

    GLP-1 therapies provide benefits in metabolic dysfunction and osteoarthritis.

  • 6

    Gaps in evidence highlight the need for more long-term studies.

Original Source(s)

Obesity Medications Get New Guidance

  • by Kathryn Wighton

  • March 17, 2026

Related Content

Elevated PFAS Linked to Changes in Blood Lipids 

Serum lipid profiling reveals PFAS-linked shifts in triglyceride and membrane lipid species 

  • March 17, 2026

  • 2 min
Oral Bacteria Linked to Bone Loss in Mouse Study

Researchers find periodontitis-associated microbiota altered gut metabolism and increased osteoclast activity in mice.

  • March 16, 2026

  • 2 min
Dual Therapy Boosts Weight Loss in Trial 

A phase 2 trial found greater results with combined bimagrumab and semaglutide than with either therapy alone